ClinicalTrials.gg
CompletedNCT06597422Updated Apr 13, 2026

A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects

A Phase 1 interventional study of STSP-0902 ophthalmic solution and STSP-0902 Placebo in Neurotrophic Keratitis, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This trial is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of STSP-0902 ophthalmic solution in healthy subjects following single and multiple administrations. The study plans to enroll 80 healthy subjects and is divided into three stages: the single-dose study stage, the multiple-dose study stage, and the tear PK study stage. The single-dose and multiple-dose study stages are randomized, double-blind, placebo-controlled, dose-escalation designs, while the tear PK study stage is a single-dose, open-label design.

02

Conditions studied

  • Neurotrophic Keratitis

Browse trials for

Keywords

  • STSP-0902
  • Ophthalmic Solution
  • Healthy Subjects
03

In context

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

This study's enrollment of 82 is above the median of 40 across 70 interventional studies indexed under Keratitis.

Browse Keratitis studies →

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects aged between 18 and 45 years (inclusive).
  2. Male subjects with a weight of ≥50.0 kg, and female subjects with a weight of ≥45.0 kg, with a (BMI) between 19.0 and 26.0 kg/m² (inclusive).
  3. Both eyes have a corrected visual acuity of ≥1.0, with normal or clinically insignificant results from eye examinations, including slit-lamp examination, intraocular pressure measurement, and fundus examination.
  4. Schirmer I test results for both eyes are ≥10 mm/5 minutes (applicable only to subjects in the tear PK study stage).
  5. Physical examination, vital signs, 12-lead , chest imaging, and laboratory tests (including hematology, urinalysis, blood chemistry, and coagulation function) are normal or clinically insignificant during the screening period.
  6. Subjects (including their partners) agree to use effective non-drug during the trial and for 6 months after the last dose and must not plan to conceive, donate sperm, or donate eggs.
  7. Subjects are fully informed about the content, process, and potential adverse effects of the trial, voluntarily sign the form, and be willing to complete the trial, follow-up, and related examinations according to the trial plan.

Exclusion criteria

Exclusion Criteria:

  1. History or current presence of any eye disease other than refractive errors (e.g., myopia, hyperopia, astigmatism).
  2. History of any eye surgery (including laser correction surgery) or having only one functional eye.
  3. Use of any topical eye medication (e.g., artificial tears, traditional Chinese medicine eye drops, antibiotic eye drops, recombinant monoclonal antibody eye drops, eye gels, etc.) within 1 month prior to screening.
  4. Wearing contact lenses within 2 weeks before screening or needing to wear contact lenses during the clinical study.
  5. abnormal results from corneal fluorescein staining (applicable only to subjects in the single-dose and multiple-dose study stages).
  6. History or current presence of any severe systemic disease, including but not limited to cardiovascular, cerebrovascular, respiratory, gastrointestinal, endocrine, metabolic, neurological, hematological, oncological, immune, infectious, or psychiatric disorders, especially those that may affect the eyes (e.g., hypertension, diabetes, hyperthyroidism).
  7. Abnormal and clinically significant results in any of the following tests: surface antigen, antibody, syphilis-specific antibody, or test.
  8. Allergy to any component of the product or , history of allergies (especially eye allergies), or a known history of food or drug allergies.
  9. Vaccination within 1 month prior to screening or planned vaccination during the trial.
  10. Use of prescription drugs, over-the-counter drugs, or herbal medicines within 2 weeks before screening.
  11. History of treatment with nerve growth factor (NGF) drugs (e.g., murine NGF) or use of other neurotrophic drugs (e.g., B vitamins, fish oil, etc.) within 3 months before screening.
  12. Underwent any major surgery within 6 months prior to screening or has plans for surgery during the trial.
  13. History of smoking within 3 months before screening, defined as smoking more than 5 cigarettes or an equivalent amount of tobacco per day on average, or inability to abstain from any tobacco products during the study.
  14. Regular alcohol consumption within 6 months before screening, defined as an average daily alcohol intake of more than 2 units (1 unit = 360 mL of beer, 45 mL of spirits with 40% alcohol, or 150 mL of wine), or a positive alcohol breath test result, or inability to abstain from any alcohol products during the study.
  15. Daily consumption of more than 5 cups of coffee or strong tea (each cup ≥150 mL) within 3 months before screening, or inability to abstain during the study.
  16. History of drug abuse (e.g., morphine, ketamine, tetrahydrocannabinol [cannabis], methamphetamine, MDMA [ecstasy], cocaine, etc.) or a positive drug abuse screening result.
  17. Blood loss or blood donation >400 mL within 3 months prior to screening, or history of blood transfusion within 4 weeks before screening, or plans to donate blood or blood components during the trial or within 3 months after the trial ends.
  18. Participation in any clinical trial and receipt of investigational drugs, devices, or vaccines within 3 months before screening.
  19. Pregnant or lactating women, those with a positive blood pregnancy test, or women who have not used effective within 2 weeks before screening.
  20. Difficulty in administering eye drops, difficulty with venipuncture, inability to tolerate venipuncture for blood sampling, or history of needle phobia or blood phobia.
  21. Any other condition that, in the investigator\'s opinion, makes the subject unsuitable for participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Single Low Dose Arm

    Low dose of STSP-0902 ophthalmic solution to study eye. Single dose.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Single Middle Dose Arm

    Middle dose of STSP-0902 ophthalmic solution to study eye. Single dose.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Single High Dose Arm

    High dose of STSP-0902 ophthalmic solution to study eye. Single dose.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Single Control Dose Arm

    STSP-0902 Placebo to study eye. Single dose.

    Drug: STSP-0902 Placebo

  • Experimental
    Multiple Low Dose Arm

    Low dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Multiple Middle Dose Arm

    Middle dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Multiple High Dose Arm

    High dose of STSP-0902 ophthalmic solution to study eye. Three times daily for a total of 8 days.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Multiple Highest Dose Arm

    Middle dose of STSP-0902 ophthalmic solution to study eye. Six times daily for a total of 8 days.

    Drug: STSP-0902 ophthalmic solution

  • Experimental
    Multiple Control Dose Arm

    STSP-0902 Placebo to study eye. Multiple doses.

    Drug: STSP-0902 Placebo

  • Experimental
    Tear PK study Arm

    STSP-0902 ophthalmic solution to both eyes. Single dose.

    Drug: STSP-0902 ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events related to study drug

    Number of participants with ocular and systemic adverse events as assessed by CTCAE v5.0.

    Time frame: Baseline to Day 28

Secondary outcomes

  1. STSP-0902 concentration

    Measurement of STSP-0902 in plasma and tear after drug administration

    Time frame: Baseline to Day 28

  2. Incidence of positive detection of anti-STSP-0902 antibodies

    Measurement of anti-drug antibody (ADA) to STSP-0902 in plasma after drug administration

    Time frame: Baseline to Day 28

07

Study locations

1 site
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100005, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jan 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Oct 20, 2024
Primary completionActual
Jan 23, 2025
CompletionActual
Jan 23, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06597422
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 20, 2024
Primary completion
Jan 23, 2025
Completion
Jan 23, 2025
Last update
Apr 13, 2026

Study contacts

Laichun Lu, Ph.D
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STSP-0902

Start the discussion